Six rounds of annual praziquantel treatment during a national helminth control program significantly reduced schistosome infection and morbidity levels in a cohort of schoolchildren in Zimbabwe.


Journal

PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488

Informations de publication

Date de publication:
06 2020
Historique:
received: 20 09 2019
accepted: 13 05 2020
revised: 02 07 2020
pubmed: 23 6 2020
medline: 15 8 2020
entrez: 23 6 2020
Statut: epublish

Résumé

The World Health Organization recommends that schistosomiasis be treated through Mass Drug Administration (MDA). In line with this recommendation, Zimbabwe commenced a national helminth control program in 2012 targeting schoolchildren throughout the country for 6 years. This study, part of a larger investigation of the impact of helminth treatment on the overall health of the children, determined the effect of annual praziquantel treatment on schistosome infection and morbidity in a cohort of children during Zimbabwe's 6-year national helminth control program. A school-based longitudinal study was carried out in 35 sentinel sites across Zimbabwe from September 2012 to November 2017. The sentinel sites were selected following a countrywide survey conducted in 280 primary schools. Schistosoma haematobium was diagnosed using the urine filtration technique. Schistosoma mansoni was diagnosed using both the Kato-Katz and formol-ether concentration techniques. S. haematobium morbidity was determined through detection of macro and microhaematuria. A cohort of children aged 6-15 years old was surveyed annually before MDA and 6 weeks post treatment. Maximum treatment coverage reached 90% over the 6 rounds of MDA. At baseline S. haematobium infection prevalence and intensity were 31.7% (95% CI = 31.1-32.2) and 28.75 eggs/10ml urine (SEM = 0.81) respectively, while S. mansoni prevalence and intensity were 4.6% (95% CI = 4.4-4.8) and 0.28 eggs/25mg (SEM = 0.02). Prior to the 6th round of MDA, S. haematobium infection prevalence had reduced to 1.56% (p<0.001) and infection intensity to 0.07 (SEM 0.02). Six weeks later after the 6th MDA, both were 0. Similarly the prevalence of S. haematobium morbidity as indicated by haematuria also fell significantly from 32.3% (95% CI = 29.9-34.6) to 0% (p< 0.0001) prior to the final MDA. For S.mansoni, both prevalence and intensity had decreased to 0 prior to the 6th MDA. After 6 rounds of annual MDA, prevalence and intensity of both schistosome species decreased significantly to 0% (p< 0.0001). Zimbabwe's helminth control program significantly reduced schistosome infection intensity and prevalence and urogenital schistosomiasis morbidity prevalence in a cohort of school-aged children, moving the schistosome prevalence in the children from moderate to low by WHO classification. These findings will inform the design of the country's next stage interventions for helminth control and eventual elimination.

Sections du résumé

BACKGROUND
The World Health Organization recommends that schistosomiasis be treated through Mass Drug Administration (MDA). In line with this recommendation, Zimbabwe commenced a national helminth control program in 2012 targeting schoolchildren throughout the country for 6 years. This study, part of a larger investigation of the impact of helminth treatment on the overall health of the children, determined the effect of annual praziquantel treatment on schistosome infection and morbidity in a cohort of children during Zimbabwe's 6-year national helminth control program.
METHODOLOGY/PRINCIPAL FINDINGS
A school-based longitudinal study was carried out in 35 sentinel sites across Zimbabwe from September 2012 to November 2017. The sentinel sites were selected following a countrywide survey conducted in 280 primary schools. Schistosoma haematobium was diagnosed using the urine filtration technique. Schistosoma mansoni was diagnosed using both the Kato-Katz and formol-ether concentration techniques. S. haematobium morbidity was determined through detection of macro and microhaematuria. A cohort of children aged 6-15 years old was surveyed annually before MDA and 6 weeks post treatment. Maximum treatment coverage reached 90% over the 6 rounds of MDA. At baseline S. haematobium infection prevalence and intensity were 31.7% (95% CI = 31.1-32.2) and 28.75 eggs/10ml urine (SEM = 0.81) respectively, while S. mansoni prevalence and intensity were 4.6% (95% CI = 4.4-4.8) and 0.28 eggs/25mg (SEM = 0.02). Prior to the 6th round of MDA, S. haematobium infection prevalence had reduced to 1.56% (p<0.001) and infection intensity to 0.07 (SEM 0.02). Six weeks later after the 6th MDA, both were 0. Similarly the prevalence of S. haematobium morbidity as indicated by haematuria also fell significantly from 32.3% (95% CI = 29.9-34.6) to 0% (p< 0.0001) prior to the final MDA. For S.mansoni, both prevalence and intensity had decreased to 0 prior to the 6th MDA. After 6 rounds of annual MDA, prevalence and intensity of both schistosome species decreased significantly to 0% (p< 0.0001).
CONCLUSION
Zimbabwe's helminth control program significantly reduced schistosome infection intensity and prevalence and urogenital schistosomiasis morbidity prevalence in a cohort of school-aged children, moving the schistosome prevalence in the children from moderate to low by WHO classification. These findings will inform the design of the country's next stage interventions for helminth control and eventual elimination.

Identifiants

pubmed: 32569278
doi: 10.1371/journal.pntd.0008388
pii: PNTD-D-19-01559
pmc: PMC7332090
doi:

Substances chimiques

Praziquantel 6490C9U457

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0008388

Subventions

Organisme : Department of Health
ID : 16/136/33
Pays : United Kingdom

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

PLoS Negl Trop Dis. 2014 Aug 14;8(8):e3014
pubmed: 25121489
PLoS Negl Trop Dis. 2015 Jun 18;9(6):e0003821
pubmed: 26086551
J Clin Microbiol. 2011 Jun;49(6):2183-90
pubmed: 21525226
Parasitol Res. 2012 Nov;111(5):1871-7
pubmed: 23052781
Philos Trans R Soc Lond B Biol Sci. 2014 May 12;369(1645):20130434
pubmed: 24821920
Trans R Soc Trop Med Hyg. 2009 Jan;103(1):45-51
pubmed: 18951599
J Helminthol. 2010 Mar;84(1):107-14
pubmed: 19646307
Acta Trop. 2006 Feb;97(2):219-28
pubmed: 16386231
PLoS One. 2015 Apr 01;10(4):e0123673
pubmed: 25830917
PLoS Negl Trop Dis. 2015 Mar 20;9(3):e0003649
pubmed: 25793584
PLoS Negl Trop Dis. 2014 Apr 10;8(4):e2651
pubmed: 24722335
PLoS Negl Trop Dis. 2012;6(7):e1758
pubmed: 22860148
Am J Trop Med Hyg. 1996 Apr;54(4):319-24
pubmed: 8615440
Biomed Res Int. 2017;2017:7035025
pubmed: 29094048
Am J Trop Med Hyg. 2017 Dec;97(6):1810-1817
pubmed: 29016344
Bull Soc Pathol Exot Filiales. 1983 Jan-Feb;76(1):101-4
pubmed: 6839402
Rev Inst Med Trop Sao Paulo. 1972 Nov-Dec;14(6):397-400
pubmed: 4675644
Expert Rev Anti Infect Ther. 2012 Aug;10(8):835-7
pubmed: 23030319
Cent Afr J Med. 1992 Dec;38(12):451-8
pubmed: 1340796
Lancet Glob Health. 2015 Oct;3(10):e629-38
pubmed: 26385302
Parasitology. 2017 Oct;144(12):1624-1632
pubmed: 27729092
Parasit Vectors. 2014 Feb 19;7:74
pubmed: 24552246
PLoS Negl Trop Dis. 2018 Nov 8;12(11):e0006813
pubmed: 30408030
Cent Afr J Med. 1988 Sep;34(9):212-21
pubmed: 3150821
BMC Infect Dis. 2014 Mar 26;14:165
pubmed: 24666689
J Adv Res. 2013 Sep;4(5):425-32
pubmed: 25685449
Lancet Infect Dis. 2017 Feb;17(2):e42-e48
pubmed: 27988094
J Parasitol Res. 2012;2012:353768
pubmed: 22655171
Acta Trop. 2009 Jul;111(1):64-70
pubmed: 19426665
Trop Geogr Med. 1988 Oct;40(4):314-7
pubmed: 3147550
Clin Infect Dis. 2016 Nov 1;63(9):1151-1159
pubmed: 27470241
PLoS Pathog. 2009 Sep;5(9):e1000571
pubmed: 19730700
Parasite Immunol. 1996 Apr;18(4):181-91
pubmed: 9223173
World Health Organ Tech Rep Ser. 2002;912:i-vi, 1-57, back cover
pubmed: 12592987
Parasite Immunol. 1997 Jun;19(6):255-63
pubmed: 9364555

Auteurs

Takafira Mduluza (T)

Department of Biochemistry, University of Zimbabwe, Mount Pleasant, Harare, Zimbabwe.
TIBA Zimbabwe, NIHR Global Health Research Unit Tackling Infections to Benefit Africa (TIBA) at the University of Edinburgh, Edinburgh, United Kingdom.

Caitlin Jones (C)

Centre for Infection, Immunity & Evolution and Institute of Immunology & Infection Research, University of Edinburgh, Ashworth Laboratories, King's Buildings, Edinburgh, United Kingdom.
NIHR Global Health Research Unit Tackling Infections to Benefit Africa (TIBA) at the University of Edinburgh, Ashworth Laboratories, King's Buildings, Edinburgh, United Kingdom.

Derick N M Osakunor (DNM)

Centre for Infection, Immunity & Evolution and Institute of Immunology & Infection Research, University of Edinburgh, Ashworth Laboratories, King's Buildings, Edinburgh, United Kingdom.

Rivka Lim (R)

Centre for Infection, Immunity & Evolution and Institute of Immunology & Infection Research, University of Edinburgh, Ashworth Laboratories, King's Buildings, Edinburgh, United Kingdom.
NIHR Global Health Research Unit Tackling Infections to Benefit Africa (TIBA) at the University of Edinburgh, Ashworth Laboratories, King's Buildings, Edinburgh, United Kingdom.

Julius K Kuebel (JK)

Centre for Infection, Immunity & Evolution and Institute of Immunology & Infection Research, University of Edinburgh, Ashworth Laboratories, King's Buildings, Edinburgh, United Kingdom.
NIHR Global Health Research Unit Tackling Infections to Benefit Africa (TIBA) at the University of Edinburgh, Ashworth Laboratories, King's Buildings, Edinburgh, United Kingdom.

Isaac Phiri (I)

Epidemiology & Disease Control, Ministry of Health and Child Care, Harare, Zimbabwe.

Portia Manangazira (P)

Epidemiology & Disease Control, Ministry of Health and Child Care, Harare, Zimbabwe.

Paradzayi Tagwireyi (P)

Department of Geography and Environmental Science, Geo-information and Earth Observation Centre, University of Zimbabwe, Mount Pleasant, Harare, Zimbabwe.

Francisca Mutapi (F)

Centre for Infection, Immunity & Evolution and Institute of Immunology & Infection Research, University of Edinburgh, Ashworth Laboratories, King's Buildings, Edinburgh, United Kingdom.
NIHR Global Health Research Unit Tackling Infections to Benefit Africa (TIBA) at the University of Edinburgh, Ashworth Laboratories, King's Buildings, Edinburgh, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH